ClinicalTrials.gg
CompletedNCT01887405HEJUpdated Jun 26, 2013

Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext

A Phase 4 interventional study of Adrenaline auto-injector in Handling of Auto-injectors, sponsored by ALK Nordic A/S, Danmark Filial. Completed at 1 site in Sweden. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-06-26.

Sponsored by ALK Nordic A/S, Danmark Filial (part of ALK-Abelló A/S) · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

The purpose of the study is to demonstrate non-inferiority of Jext compared with EpiPen for the proportion of subjects with a successful self-injection. And to evaluate and compare the handling characteristics of two auto-injectors (Jext and EpiPen).

02

Conditions studied

  • Handling of Auto-injectors

Keywords

  • Adrenaline
  • Auto-injector
  • Jext
  • Epipen
03

In context

Lead sponsor

This is the only study on the registry with ALK Nordic A/S, Danmark Filial as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained before entering the study 1
  • Prescription of EpiPen or AnaPen for at least 2 months
  • Age ≥16 years
  • Body weight >50 kg
  • Subject willing and able to comply with study protocol

Exclusion criteria

Exclusion Criteria:

  • Any of the following concomitant diseases: cardiovascular disease, e.g. arrhythmias or signs of coronary atherosclerosis, heart failure, uncontrolled hypertension, uncontrolled diabetes mellitus, cancer, hyperthyroidism, severe renal impairment
  • Known blood-born infection, e.g. hepatitis and/or
  • Concomitant treatment with medication which may potentiate the effect of adrenaline, e.g. catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase (MAO) inhibitors and tricyclic antidepressants
  • Pregnancy
  • Being immediate family of the investigator or study staff, defined as the investigator's/staff's spouse, parent, child, grandparent or grandchild
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Active comparator
    Adrenaline: Session 1 Jext, 2 Epipen

    Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.

    Drug: Adrenaline auto-injector

  • Active comparator
    Adrenaline: Session 1 Epipen, 2 Jext

    Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.

    Drug: Adrenaline auto-injector

Interventions

  • Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session. Valid for both Jext and Epipen: Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water

    Also known as: Jext, Epipen

06

What researchers measure

Primary outcomes

  1. Non-inferiority of Jext compared with EpiPen for the proportion of subjects with a successful self-injection.

    The following steps were recorded as correctly done or not by the observer in a check list approach (yes/no): 1. The subject identified the safety cap. 2. The subject removed the safety cap. 3. The subject identified the end of the auto-injector where the needle presents itself 4. The subject used sufficient force to actuate the injection. 5. The subject injected the auto-injector into the anterolateral thigh at a right angle (approximately 90°) to the thigh. 6. The time spent for the injection of adrenaline was more than 10 seconds, i.e. with the needle in situ. If all 6 steps were performed correctly, the injection was considered as successful. These data form the basis for evaluation of the binary primary endpoint (successful injection or not).

    Time frame: 1 day

Secondary outcomes

  1. To evaluate and compare the handling characteristics of two auto-injectors (Jext and EpiPen) regarding subject preference for one of the two auto-injectors over the other, the time to perform the injection and any hesitance to perform the injection

    For evaluation of the secondary endpoints, the observer assessed the following: The time used for the actuation of the injection, i.e. the time from starting to read the instructions to having injected the adrenaline as recorded by a stop watch. This time was divided into two parts: * The time for reading the information * The time used to perform the injection Any hesitation from the subject to actuate the injection on a 4-step scale: None, Minor, Severe or Completely Inhibited (i.e. no injection) At the end of the second session the subject was asked the following question: "Which auto-injector do you prefer?" The following responses were possible: Jext / EpiPen / I don't have any preference for any of the auto-injectors. The preference is a secondary endpoint.

    Time frame: 1 day

Other outcomes

  1. Evaluation of instructions and AEs

    After the injection the subject evaluated the package of instructions (leaflet as well as the information on the auto-injector) for the following (yes/no): Were the instructions concise? Were the instructions comprehensible? Do you have any further questions concerning the instructions or do you see any lack of clarity? These have been assessed as other endpoints. Safety assessments included recording of all AEs and serious adverse events (SAEs) were done.

    Time frame: 1 day

07

Study locations

1 site
  • Asthma and Allergy Clinic at St Göran's Hospital
    Stockholm, 11281, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2013
First posted
Jun 26, 2013
Start
Jan 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Jun 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01887405
Responsible party
Sponsor
First posted
Jun 26, 2013
Start date
Jan 2012
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Jun 26, 2013

Study contacts

Victoria Strand, MD Phd
principal investigator · Asthma and Allergy Clinic at St Göran's Hospital, Stockholm, Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epinephrine

Start the discussion